Comparative Pharmacology
Head-to-head clinical analysis: GLEOLAN versus LEVULAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLEOLAN versus LEVULAN.
GLEOLAN vs LEVULAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gleolan (aminolevulinic acid hydrochloride) is a photosensitizing agent that induces accumulation of protoporphyrin IX (PpIX) in malignant glioma cells. Selective fluorescence under blue light (405 nm) enables intraoperative visualization of tumor tissue.
Levulan (aminolevulinic acid) is a photosensitizing agent. It is converted intracellularly into protoporphyrin IX, which accumulates in cells. Upon exposure to light of appropriate wavelength, protoporphyrin IX generates reactive oxygen species, leading to cellular damage and apoptosis.
125 mg orally once daily with food.
20% topical solution applied to lesion and surrounding 5 mm of normal skin; then illuminated with blue light (417 nm) for 1000 seconds (16 minutes 40 seconds) 14 to 18 hours after application.
None Documented
None Documented
Terminal elimination half-life is approximately 7.4 hours (range 5.8–10.3 h) in patients with normal hepatic function; prolonged in hepatic impairment, supporting once-daily dosing.
Topical: aminolevulinic acid (ALA) has a terminal half-life of approximately 1–2 hours in plasma; protoporphyrin IX (PpIX) accumulates locally and persists for 24–48 hours.
Primarily hepatic metabolism via CYP3A4, with 88% of radiolabeled dose recovered in feces (87% unchanged) and 1% in urine, indicating negligible renal elimination.
Primarily fecally (biliary) as protoporphyrin IX; renal excretion is negligible (<4% of absorbed dose).
Category C
Category C
Photosensitizer
Photosensitizer